Biotechnology
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

$166M

Market Cap • 12/26/2024

2018

(6 years)
Founded

2021

(3 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Waltham

Headquarters • Massachusetts